Solasia Pharma K.K.
Recognition of License Agreement Revenue (Sancuso® Split Payment) and Notice of Revision to 2026 Product Sales Revenue and Cost of Goods Sold Estimates
Reporting partial recognition of Sancuso split payment revenue for fiscal 2026 related to the agreement with MAAB. Revised the 2026 product sales revenue estimate to 350 million yen and cost of goods sold estimate to 190 million yen. The overall expected amount of license revenue and timing of further disclosure remain withheld.
Key Figures
- Partial recognition of Sancuso split payment revenue (Unknown)
- 2026 product sales revenue estimate = 350 million yen
- 2026 cost of goods sold estimate = 190 million yen
AI要約
Key News Points
Partial recognition of the Sancuso® split payment revenue is planned in the current fiscal settlement in relation to the agreement with MAAB. The 2026 product sales revenue estimate has been revised to 350 million yen and the cost of goods sold estimate to 190 million yen. The overall license revenue outlook and timing of any further disclosures will continue to be withheld.
Future Impact and Considerations
Depressed shipment levels are affecting the 2026 revenue outlook, and external factors such as foreign exchange may also impact results. Only certain previously disclosed items have been revised; publication of the overall forecast remains withheld.
Solasia Pharma K.K.
Company overview · Stock price · Financial data · All IR
